Publications by authors named "Juliachs M"
Article Synopsis
- There's a high demand for non-invasive methods to detect early responses to cancer treatments, particularly through measuring circulating tumor biomarkers.
- Researchers focused on manganese superoxide dismutase (SOD2), a resilient protein, which was found to correlate with cancer cell death during chemotherapy in breast cancer.
- Increased levels of SOD2 in the blood of patients responding to neoadjuvant therapy suggest that tracking this protein could enhance non-invasive monitoring and evaluation of cancer treatments over time.
Article Synopsis
- Researchers studied the genetic causes of cisplatin resistance in testicular germ cell tumors by transplanting human tumors into mice, which maintained key tumor characteristics and drug sensitivity.
- They found that tumors resistant to cisplatin showed specific chromosomal alterations, particularly gains in the 9q32-q33.1 region, which were associated with poorer survival rates in patients.
- The study identified several deregulated genes in the resistant tumors and suggested that inhibiting the glucosylceramide synthase (GCS) could help overcome cisplatin resistance, highlighting the potential of orthoxenografts for drug testing and identifying resistance markers.
Purpose: The lack of secreted biomarkers measurable by noninvasive tests hampers the development of effective targeted therapies against cancer. Our hypothesis is that cetuximab (an anti-EGFR mAb) induces a specific secretome in colorectal cancer cells that could be exploited for biomarker discovery.
Experimental Design: Considering the strong correlation between mutated KRAS and a lack of response to cetuximab therapy, we addressed whether performing secretome-based proteomics on isogenic colorectal cancer cells sharing the KRAS mutations found on patients would yield candidate-secreted biomarkers useful in the clinical setting.
Purpose: We examined whether PI3K-AKT or extracellular signal-regulated kinase (ERK) signaling pathways could play a role in the development of cisplatin (CDDP) resistance in testicular germ cell tumor (TGT) cells.
Experimental Design: We compared AKT and ERK activation levels in CDDP-sensitive testicular tumor cells and in their corresponding CDDP-resistant-derived cells. We also analyzed these pathways in orthotopic testicular tumors and human patient samples.
Background: Cisplatin (CDDP) resistance in testicular germ cell tumors (GCTs) is still a clinical challenge, and one associated with poor prognosis. The purpose of this work was to test pazopanib, an anti-tumoral and anti-angiogenic multikinase inhibitor, and its combination with lapatinib (an anti-ErbB inhibitor) in mouse orthotopic models of human testicular GCTs.
Methods: We used two different models of human testicular GCTs orthotopically grown in nude mice; a CDDP-sensitive choriocarcinoma (TGT38) and a new orthotopic model generated from a metastatic GCT refractory to first-line CDDP chemotherapy (TGT44).
In this work, we have analyzed the expression of different members of the ErbB family in human samples of testicular germ cell tumors (GCTs). We observed expression of ErbB1 or ErbB2 in different tumor subtypes, but we also found high expression of ErbB3 in all GCTs tested. This pattern of expression was maintained when primary tumors were orthotopically implanted in nude mice.
View Article and Find Full Text PDF